Natroba

Natroba is a brand name of spinosad topical, approved by the FDA in the following formulation(s):

NATROBA (spinosad - suspension; topical)

• 
  Manufacturer: PARAPRO PHARMS
  
  Approval date: January 18, 2011
  
  Strength(s): 0.9% ^[RLD]

Has a generic version of Natroba been approved?

No. There is currently no therapeutically equivalent version of Natroba available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Natroba. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Insecticide and miticide A83543 compounds and their method of production by fermentation
  Patent 5,496,931
  Issued: March 5, 1996
  Inventor(s): Boeck; LaVerne D. & Chio; Hang & Eaton; Tom E. & Godfrey, Jr.; Otis W. & Michel; Karl H. & Nakatsukasa; Walter M. & Yao; Raymond C.
  Assignee(s): DowElanco
  Fermentation product A83543, comprising major components A83543A and A83543D and minor components A83543B, A83543C, A83543E, A983543F, A83543G, A83543H and A83543J, is produced by a newly described species, Saccharopolyspora spinosa. The A83543 components and their acid-addition salts (A83543 compounds) are useful as insecticides, particularly against Lepidoptera and Diptera species. Insecticidal, miticidal or ecto-parasiticidal combinations, compositions and methods are provided.
  
  Patent expiration dates:
  
  
  • March 5, 2013
    
    ✓ 
    Patent use: TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER
    ✓ 
    Drug substance
  
  



• 
  Formulations for controlling human lice
  Patent 6,063,771
  Issued: May 16, 2000
  Inventor(s): Snyder; Daniel Earl
  Assignee(s): Eli Lilly and Company
  Safer pediculicidal formulations comprising a spinosyn, or a physiologically acceptable derivative or salt thereof, and a physiologically acceptable carrier, and methods of controlling lice infestations in a human with these formulations are provided.
  
  Patent expiration dates:
  
  
  • June 22, 2019
    
    ✓ 
    Patent use: TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER
    ✓ 
    Drug product
  
  



• 
  Formulations for controlling human lice
  Patent 6,342,482
  Issued: January 29, 2002
  Inventor(s): Daniel Earl; Snyder
  Assignee(s): Eli Lilly and Company
  Safer pediculicidal formulations comprising a spinosyn, or a physiologically acceptable derivative or salt thereof, and a physiologically acceptable carrier, and methods of controlling lice infestations in a human with these formulations are provided.
  
  Patent expiration dates:
  
  
  • June 22, 2019
    
    ✓ 
    Patent use: TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER
    ✓ 
    Drug product
  
  



• 
  Pediculicidal and ovacidal treatment compositions and methods for killing head lice and their eggs
  Patent 7,030,095
  Issued: April 18, 2006
  Inventor(s): Janssen; Herwig & Ho; Kie & Nystrand; Glenn & Williams; Dexter & Lamb; C. Scott
  Assignee(s): Johnson & Johnson Consumer Companies, Inc.
  The present invention relates to composition and methods for administering compositions in solutions for killing adult lice and the ova comprising water, PVM/MA Decadiene crosspolymers, propylene glycol, a mixture of cetyl and stearyl alcohols, Ceteareth-20; stearalkonium chloride; benzyl alcohol; hexylene glycol; pentylene glycol, isopropyl alcohol; a mixture of spinosyn A and spinosyn D in a weight ratio of 80:20, BHT; and sodium hydroxide.
  
  Patent expiration dates:
  
  
  • July 2, 2021
    
    ✓ 
    Patent use: TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • January 18, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Natroba Consumer Information (Drugs.com)
• Natroba Suspension Consumer Information (Wolters Kluwer)
• Natroba Consumer Information (Cerner Multum)
• Natroba Advanced Consumer Information (Micromedex)
• Spinosad Suspension Consumer Information (Wolters Kluwer)
• Spinosad topical Consumer Information (Cerner Multum)
• Spinosad Topical application Advanced Consumer Information (Micromedex)